Gergely Á. Visolyi

Gergely Á. Visolyi

Auto-generated profile, based on publicly available information

Gergely Á. Visolyi

Károly Rácz School of PhD Studies, Semmelweis University, Budapest, Hungary; Department of Internal Medicine and Oncology, Semmelweis University Faculty of Medicine, Budapest, Hungary

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 March 2023 in Canadian Journal of Diabetes
Verified
Journal Article
Open access
GVGergely Á. Visolyi
Gergely Á. Visolyi
BDBeatrix A. Domján
Beatrix A. Domján
MSMárk M. Svébis
Márk M. Svébis
APAnna Péterfi
Anna Péterfi
BLBarbara D. Lovász
Barbara D. Lovász
ATAdam Tabak
Adam Tabak
Our aim in this study was to compare the efficacy and safety of commercially available fixed-ratio combinations (FRCs) of glucagon-like peptide-1 receptor agonists (GLP-1RAs) and basal insulins by a network meta-analysis of randomized controlled trials (RCTs) of people with type 2 diabetes. We present a systematic review and network meta-analyses of RCTs of individuals with type 2 diabetes randomized to FRCs or to their components for ≥24 weeks. All reports were obtained from PubMed or ClinicalTrials.gov up to February 28, 2022. The primary outcome was glycated hemoglobin (A1C) level attained. Secondary outcomes included fasting plasma glucose, change in body weight, and incident hypoglycemia. Treatment effects were estimated as mean difference (MD) and standard error (SE), or as odds ratio (OR) with 95% confidence interval (CI) using the fixed combination of insulin glargine 100 IU/mL and lixisenatide (iGlarLixi) as reference. We included 29 RCTs from among the 1,404 articles identified. No direct comparisons between FRCs were found. After excluding some insulin-capped trials to reach model consistency, both FRCs were more efficacious regarding A1C than their components, but no difference between FRCs was found (MD, -0.10%; SE, 0.10%). The effect of the fixed combination of insulin degludec and liraglutide (IDegLira) (MD, -0.47 mmol/L; SE, 0.24 mmol/L) and basal insulins was similar to that of iGlarLixi (reference) on fasting glucose, whereas GLP-1RAs had lower efficacy than iGlarLixi. Weight gain was lower with GLP-1RAs and IDegLira (MD, -0.72 kg; SE, 0.32 kg) than with iGlarLixi (reference) and higher with basal insulins. Incident hypoglycemia (based on different definitions) was least frequent with GLP-1RAs, followed by IDegLira (OR, 0.78; 95% CI, 0.39 to 1.57), iGlarLixi (reference), and basal insulins. For A1C, both FRCs were more efficacious over their individual components, with similar efficacies of the 2 FRCs.

12 August 2023 in Diabetes Research and Clinical Practice
Verified
Journal Article
Open access
GVGergely Á. Visolyi
Gergely Á. Visolyi
AKAttila Kun
Attila Kun
OSOrsolya Szalai
Orsolya Szalai
MSMárk M. Svébis
Márk M. Svébis
BDBeatrix A. Domján
Beatrix A. Domján
ATAdam Tabak
Adam Tabak
We compared pregnancy outcomes of untreated 'mild' GDM (GDM by WHO 2013 but not by WHO-1999) to normal glucose tolerant women (NGT). In a universal screening program 4333 pregnant women had a 3-point 75 g OGTT in Hungary in 2009-2013. By WHO-2013 untreated NGT was diagnosed in n = 3303, 'mild' GDM in n = 336 cases. 'Mild' GDM women were older (mean difference, SE: 1.4, 0.3 yrs), had higher fasting (1.0, 0.02), 60-minute (1.0, 0.09), and 120-minute (0.4, 0.06 mmol/l) blood glucose, and blood pressure (2.6, 0.5/2.0, 0.5 mmHg). Weight gain was similar in both groups (-0.3, 0.3 kg). GDM newborns were heavier (142, 50 g) and were more frequently macrosomic (>4000 g, OR 1.85, 95 %CI 1.35-2.54). Hypertension during pregnancy was more prevalent in the GDM group (OR 1.55, 95 %CI 1.05-2.28), as well as induced (OR 1.38, 95 %CI 1.10-1.74) and instrumental delivery (OR 1.34, 95 %CI 1.07-1.68), and acute caesarean section (OR 1.32, 95 %CI 1.04-1.64). Most of these differences substantially attenuated or became non-significant after adjustment for pre-pregnancy BMI. Pregnancy outcomes of 'mild' GDM were worse compared to normal glucose tolerant women however these differences were explained by the pre-pregnancy BMI difference between groups.

1 January 2021 in Diabetologia Hungarica
Verified
Journal Article
Open access
AKAttila Kun
Attila Kun
GVGergely Á. Visolyi
Gergely Á. Visolyi
MSMárk M. Svébis
Márk M. Svébis
ATAdam Tabak
Adam Tabak

1 January 2021 in Diabetologia Hungarica
Verified
Journal Article
Open access
VHViktor Horváth
Viktor Horváth
OVOrsolya Vági
Orsolya Vági
CKCsaba Koós
Csaba Koós
MSMárk M. Svébis
Márk M. Svébis
BDBeatrix Domján
Beatrix Domján
ÁGÁdám Tabák Gy.
Ádám Tabák Gy.